ARTICLE | Clinical News
Adcetris brentuximab vedotin regulatory update
May 28, 2012 7:00 AM UTC
Seattle Genetics said Health Canada accepted for review an NDS for Adcetris brentuximab vedotin to treat relapsed Hodgkin's lymphoma and systemic anaplastic large cell lymphoma (ALCL). Seattle Genetics is seeking conditional approval for the antibody-drug conjugate (ADC) composed of an anti- CD30 mAb and monomethyl auristatin E (MMAE). Seattle hopes to launch the product in Canada by early 2013. ...